Showing Results for
- Academic Journals (30)
Search Results
- 30
Academic Journals
- 30
- Search Terms:
- 1From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedKnown risk factors account for about 10-15% of breast cancer incidence suggesting that lifestyle exposures are crucial in its etiology. Previous epidemiological studies on the association between coffee and tea...
- 2From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedAdult human mesenchymal stem cells (hMSCs) have been shown to home to sites of breast cancer and integrate into the tumor stroma. We demonstrate here the effect of hMSCs on primary breast tumor growth and the...
- 3From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedIn a previous study from our laboratory, high tumor levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) have been associated with an adverse response to chemotherapy in metastatic breast cancer suggesting that...
- 4From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedBackground: Sentinel lymph node (SLN) biopsy is a selective approach to axillary staging of breast cancer with reduced morbidity. Current detection methods including radioisotope and blue dye show good results but some...
- 5From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedThe scaffold attachment factors SAFB1 and SAFB2 have been shown to function as estrogen receptor (ER[alpha]) co-repressors in breast cancer cells, and to affect many cellular processes such as stress response, RNA...
- 6From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedThe complexity of breast cancer biology makes it challenging to analyze large datasets of clinicopathologic and molecular attributes, toward identifying the key prognostic features and producing systems capable of...
- 7From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedAromatase inhibition (AI) is the most effective endocrine treatment for breast cancer in post-menopausal patients, but a percentage of hormone receptor-positive cancers do not benefit from such therapy: for example,...
- 8From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedThe goal of this study was to develop pharmacogenomic predictors in response to standard chemotherapy drugs in breast cancer cell lines and test their predictive value in patients who received treatment with the same...
- 9From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedThe epithelial transmembrane glycoprotein E-cadherin (CDH1) is necessary for intercellular adhesion, cell signaling, and maintenance of cellular differentiation; reduced expression contributes to cell proliferation,...
- 10From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedCumulative data suggest that some chemotherapeutic agents may be less effective in estrogen receptor [alpha] positive (ER+) breast tumors than ER negative (ER-) tumors, which has raised a clinically relevant question as...
- 11From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedTo determine whether authors conducting economic analyses of aromatase inhibitors in breast cancer are less likely to reach unfavorable conclusions if the economic study is sponsored by the manufacturer of the drug....
- 12From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedThe aim of the study is to use the EQ-5D instrument to evaluate the long-term health states of women with early stage breast cancer treated by breast-conserving surgery and radiation. A total of 1,050 women treated with...
- 13From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedPatients with ER/PR/HER2-negative (triple negative) breast cancer are not candidates for hormonal therapy or HER2-targeted agents. Ongoing research is aimed at identifying and understanding the benefit of established...
- 14From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedUncontrolled proliferation is a defining feature of the malignant phenotype. Ki67 is a marker for proliferating cells and is overexpressed in many breast cancers. Atypical hyperplasia is a premalignant lesion of the...
- 15From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedWomen with BRCA1 and BRCA2 mutations have an elevated risk of breast cancer and ovarian cancer, but also of developing second primary breast cancer. BRCA1/2 mutation carriers with breast cancer must choose between...
- 16From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedMultidrug resistance (MDR) is one of the main challenges in the treatment of breast cancer. A new microsphere formulation able to generate reactive oxygen species (ROS) locally was thus investigated for circumventing...
- 17From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedBreast cancer is a complex disease and in recent years a number of breast cancer susceptibility genes have been identified, but the role of low penetrance susceptibility genes has not been completely resolved....
- 18From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedBreast cancer is the most common cancer in women worldwide, accounting for just over 1 million new cases annually. Population-based statistics show that globally, when compared to whites, women of African ancestry (AA)...
- 19From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedThe aim of this study was to evaluate the impact of a twice-weekly strength training intervention on perceptions of body image in 234 breast cancer survivors (112 with lymphedema) who participated in the Physical...
- 20From: Breast Cancer Research and Treatment. (Vol. 121, Issue 2) Peer-ReviewedVitamin D and calcium intake have been suggested to have protective effects against breast cancer; however, the data have been inconclusive. The present meta-analysis examined the overall effects of vitamin D intake,...